NASDAQ:MRTX - Mirati Therapeutics Stock Price, Forecast & News

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics Inc (NASDAQ:MRTX) released its earnings results on Monday, November, 4th. The biotechnology company reported ($1.38) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.25) by $0.13. The biotechnology company earned $0.99 million during the quarter, compared to analysts' expectations of $0.50 million. Mirati Therapeutics had a negative return on equity of 48.60% and a negative net margin of 2,698.66%. View Mirati Therapeutics' Earnings History.

Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Mirati Therapeutics.

16 equities research analysts have issued 12 month target prices for Mirati Therapeutics' stock. Their forecasts range from $81.00 to $130.00. On average, they anticipate Mirati Therapeutics' share price to reach $107.21 in the next year. This suggests a possible upside of 10.5% from the stock's current price. View Analyst Price Targets for Mirati Therapeutics.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.

News articles about MRTX stock have trended very negative recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mirati Therapeutics earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Mirati Therapeutics.

Mirati Therapeutics saw a drop in short interest during the month of December. As of December 13th, there was short interest totalling 4,410,000 shares, a drop of 9.4% from the November 28th total of 4,870,000 shares. Based on an average daily volume of 676,400 shares, the days-to-cover ratio is currently 6.5 days. Approximately 11.4% of the shares of the company are short sold. View Mirati Therapeutics' Current Options Chain.

Some companies that are related to Mirati Therapeutics include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Bausch Health Companies (BHC), Beigene (BGNE), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Horizon Therapeutics (HZNP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Arrowhead Pharmaceuticals (ARWR), Netflix (NFLX), Viking Therapeutics (VKTX), AbbVie (ABBV), Bausch Health Companies (BHC), Advanced Micro Devices (AMD), Amarin (AMRN) and Exelixis (EXEL).

Mirati Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.32%), Tocqueville Asset Management L.P. (0.01%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Jamie Christensen, Michael G Grey and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

MRTX stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Tocqueville Asset Management L.P. and Nisa Investment Advisors LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MRTX stock can currently be purchased for approximately $97.05.

Mirati Therapeutics has a market capitalization of $3.83 billion and generates $12.93 million in revenue each year. The biotechnology company earns $-98,420,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.View Additional Information About Mirati Therapeutics.

The official website for Mirati Therapeutics is http://www.mirati.com/.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]